PowderJect signs $90 million agreement with Ares-Serono
This article was originally published in Clinica
Drug delivery company PowderJect Pharmaceuticals stands to gain up to $90 million following a worldwide, exclusive agreement with the Ares-Serono group to develop its needleless dry powder injection device, the PowderJect System. The deal covers the delivery of undisclosed therapeutic proteins from Ares-Serono - probably in the company's chief areas of reproductive health and immunology. PowderJect's shares immediately rose by 20% to 850p. As Clinica went to press, shares were valued at 887.5p.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.